NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene’s myvac™ Platform

NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene’s myvac™ Platform

NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene’s myvac™ Platform

NEC Corporation (NEC)(TOKYO:6701) and Transgene (Euronext Paris:TNG) today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid cancers. The companies will cooperate in clinically assessing the predictive capabilities of NEC’s artificial intelligence (AI) and the therapeutic potential of Transgene’s myvac™ MVA-based viral vector platform in an individualized immunotherapy for the treatment of solid cancers. The experimen...